EnteroMedics Inc. (ETRM) Sees Significant Growth in Short Interest
EnteroMedics Inc. (NASDAQ:ETRM) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 3,349,173 shares, an increase of 36.5% from the August 31st total of 2,452,796 shares. Currently, 12.8% of the company’s shares are short sold. Based on an average daily volume of 7,274,540 shares, the short-interest ratio is presently 0.5 days.
An institutional investor recently bought a new position in EnteroMedics stock. Hudson Bay Capital Management LP purchased a new stake in EnteroMedics Inc. (NASDAQ:ETRM) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 204,836 shares of the medical device company’s stock, valued at approximately $198,000. Hudson Bay Capital Management LP owned approximately 2.88% of EnteroMedics as of its most recent SEC filing. Hedge funds and other institutional investors own 5.82% of the company’s stock.
ETRM has been the subject of several analyst reports. Zacks Investment Research raised EnteroMedics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Tuesday, August 9th. Roth Capital lowered EnteroMedics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Thursday, June 9th.
EnteroMedics (NASDAQ:ETRM) opened at 0.1435 on Friday. The stock has a 50 day moving average price of $0.16 and a 200 day moving average price of $0.48. The company’s market capitalization is $3.92 million. EnteroMedics has a 52-week low of $0.11 and a 52-week high of $4.95.
EnteroMedics (NASDAQ:ETRM) last released its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.26. EnteroMedics had a negative net margin of 4,157.93% and a negative return on equity of 1,361.34%. Equities research analysts forecast that EnteroMedics will post ($2.37) earnings per share for the current year.
EnteroMedics Company Profile
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Stock Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related stocks with our FREE daily email newsletter.